ArticleMethods in molecular biology (Clifton, N.J.)2026
Identification of a Ubiquitin-Independent Degron by a Reporter Assay.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ubiquitin-independent degradation (UID) by the 20S proteasome represents a key pathway for mainly regulating intrinsically disordered proteins (IDPs), yet the degron motifs that govern this process remain poorly defined. In this chapter, we describe experimental strategies to identify UID degrons that mediate degradation by the catalytic 20S proteasome particle. Combining high-throughput 20S substrate assays in vitro with analyses of PSMA3 C-terminal binding proteins, we identified numerous IDPs, including p21, as potential substrates. Using bimolecular fluorescence complementation (BiFC) and split-luciferase reporter assays, we mapped the degron within p21. Systematic mutagenesis and peptide- and fragment-based assays delineated the minimal degron sequence, while CRISPR-Cas9-mediated editing of the endogenous protein confirmed its physiological role in proteasomal turnover. This integrated workflow-spanning degron mapping to functional validation-provides a generalizable framework for uncovering ubiquitin-independent degrons.
Indexed as
Identifiers
42573687What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.